Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00166322

Enrollment

Registered

2005-09-14

Start date

2004-01-31

Completion date

2007-12-31

Last updated

2008-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

IBZM-SPECT, Amphetamine Challenge, Schizophrenia, dopaminergic neurotransmission, Persons at risk for the development of schizophrenia, healthy subjects

Brief summary

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Interventions

PROCEDUREIBZM-SPECT (bolus and constant infusion paradigm)

single IBZM-SPECT assessment at study inclusion

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of schizophrenia (currently unmedicated) * Subjects at risk for the development of schizophrenia (prodromal symptoms) * Healthy subjects * Written informed consent

Exclusion criteria

* Neurological or severe somatic disorders * Women during pregnancy or lactation * Occupational exposition to radiation \> 15mSv * Medication known to interfere with IBZM * Contraindications for the use of amphetamine challenge

Design outcomes

Primary

Measure	Time frame
dopamine receptor availability	cross-sectional

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026